Stephanie Nahas-Geiger, MD
Neurology · Philadelphia, PANPI 1033265004
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (49.9%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by AbbVie at 37.3% of the total. Reporting peaked in 2020 at $206,042 and has fallen 66.3% since, to $69,428 in 2025. Among neurology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,187 payments — averaging $662.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$293K
- Lilly USA, LLC$218K
- Teva Pharmaceuticals USA, Inc.$120K
- Amgen$44K
- Pfizer$29K
- Lundbeck LLC$26K
- plus $55K from 24 others
Across 1 payment — averaging $90,000 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Teva Pharmaceuticals USA, Inc.$90K
What the payments were for
- Consulting fees$322,38041%
- Speaking & faculty fees$392,08850%
- Grants$420%
- Travel & lodging$45,2896%
- Food & beverage$26,0593%
- Education$1610%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 424 | $293,349 |
| Lilly USA, LLC | 304 | $217,543 |
| Teva Pharmaceuticals USA, Inc. | 136 | $120,428 |
| Amgen | 67 | $44,283 |
| Pfizer | 44 | $28,930 |
| Lundbeck LLC | 33 | $26,228 |
| Amneal Pharmaceuticals LLC | 12 | $11,186 |
| H. Lundbeck A S | 2 | $10,625 |
| Biodelivery Sciences International, Inc. | 15 | $9,347 |
| Axsome Therapeutics, Inc. | 12 | $6,901 |
| Supernus Pharmaceuticals, Inc. | 61 | $5,669 |
| Tonix Medicines, Inc. | 5 | $3,778 |
| Novartis | 24 | $3,026 |
| Biohaven Pharmaceuticals, Inc. | 5 | $2,754 |
| Bausch Health US, LLC | 1 | $625 |
| Impel Pharmaceuticals Inc. | 9 | $442 |
| Biohaven Pharmaceutical Holding Company Ltd. | 8 | $241 |
| Eli Lilly | 5 | $214 |
| Biotissue Holdings Inc. | 1 | $111 |
| Upsher-smith Laboratories LLC | 5 | $91 |
| Collegium Pharmaceutical, Inc. | 4 | $57 |
| Biogen | 1 | $30 |
| Ipsen Biopharmaceuticals, Inc | 2 | $27 |
| Eisai Inc. | 1 | $27 |
| Idorsia Pharmaceuticals US Inc | 1 | $23 |
| Impel Pharmaceuticals LLC | 1 | $20 |
| Avanir Pharmaceuticals, Inc. | 1 | $18 |
| Promius Pharma LLC | 1 | $16 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Assertio Therapeutics, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AJOVY$118,459
- UBRELVY$112,755
- BOTOX$95,180
- AIMOVIG$44,986
- EMGALITY$35,482
- NURTEC ODT$30,771
- QULIPTA$30,672
- VYEPTI$29,207
- REYVOW$25,502
- ELYXYB - CELECOXIB$8,925
- BREKIYA$7,633
- TROKENDI XR$5,000
- ZEMBRACE SYMTOUCH$3,749
- TOSYMRA$2,000
- Trudhesa$239
- ZAVZPRET$135
- Prokera$111
- AmnioGraft$111
- Austedo XR$101
How this compares
$786,019 in reported general payments places this provider in the 95th percentile of 941 neurology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 72 | $128,206 |
| UbrelvyUbrogepant | 56 | $74,641 |
| Aimovig AutoinjectorErenumab-Aooe | 73 | $58,393 |
| QuliptaAtogepant | 44 | $53,764 |
| Emgality PenGalcanezumab-Gnlm | 41 | $27,561 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 27 | $24,538 |
| ReyvowLasmiditan Succinate | 25 | $22,132 |
| Dihydroergotamine Mesylate | 19 | $12,774 |
| Sumatriptan Succinate | 126 | $11,614 |
| TrintellixVortioxetine Hydrobromide | 13 | $6,407 |
| Mexiletine Hcl | 46 | $6,305 |
| Topiramate | 63 | $1,997 |
| Duloxetine Hcl | 46 | $1,238 |
| Gabapentin | 27 | $849 |
| Candesartan Cilexetil | 24 | $798 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Qulipta | $293,349 | $128,406100 claims |
| PfizerNurtec Odt | $28,930 | $128,20672 claims |
| Lilly USA, LLCReyvow, Olanzapine | $217,543 | $22,39049 claims |
| Upsher-smith Laboratories LLCTopiramate | $91 | $1,99763 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 941 neurology providers in Pennsylvania.
Other neurology in Philadelphia
- Daniel KremensPhiladelphia$1.8M
- Thomas LeistPhiladelphia$1.4M
- Jill Giordano FarmerPhiladelphia$1.2M
- Amit Bar-OrPhiladelphia$596K
- Stephen SilbersteinPhiladelphia$428K
- Joseph BergerPhiladelphia$384K
- Sami KhellaPhiladelphia$285K
- Clyde MarkowitzPhiladelphia$274K
- Matthew SternPhiladelphia$251K
- Michelle DoughertyPhiladelphia$236K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.